Login to Your Account

Financings Roundup

Bluebird Soaring with $60M Series D for Gene Therapy

By Jennifer Boggs
Managing Editor

Wednesday, July 25, 2012
Only days after the first gene therapy finally cleared regulatory hurdles in Europe, Cambridge, Mass.-based gene therapy firm bluebird bio closed a $60 million Series D financing round.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription